A Validated Scale for Assessing the Severity of Acute Infectious Mononucleosis - 23/05/19
, Caroline Reuter, MD 1, Yair Lupovitch 3, Kristen Gleason, PhD 2, Damani McClellan, BA 2, Joseph Cotler, PhD 2, Leonard A. Jason, PhD 2Abstract |
Objectives |
To develop a scale for the severity of mononucleosis.
Study design |
One to 5 percent of college students develop infectious mononucleosis annually, and about 10% meet criteria for chronic fatigue syndrome (CFS) 6 months following infectious mononucleosis. We developed a severity of mononucleosis scale based on a review of the literature. College students were enrolled, generally when they were healthy. When the students developed infectious mononucleosis, an assessment was made as to the severity of their infectious mononucleosis independently by 2 physicians using the severity of mononucleosis scale. This scale was correlated with corticosteroid use and hospitalization. Six months following infectious mononucleosis, an assessment is made for recovery from infectious mononucleosis or meeting 1 or more case definitions of CFS.
Results |
In total, 126 severity of mononucleosis scales were analyzed. The concordance between the 2 physician reviewers was 95%. All 3 hospitalized subjects had severity of mononucleosis scores ≥2. Subjects with severity of mononucleosis scores of ≥1 were 1.83 times as likely to be given corticosteroids. Students with severity of mononucleosis scores of 0 or 1 were less likely to meet more than 1 case definition of CFS 6 months following infectious mononucleosis.
Conclusions |
The severity of mononucleosis scale has interobserver, concurrent and predictive validity for hospitalization, corticosteroid use, and meeting criteria for CFS 6 months following infectious mononucleosis.
Le texte complet de cet article est disponible en PDF.Keywords : infectious mononucleosis, chronic fatigue syndrome, severity of mononucleosis, hospitalization, steroids
Abbreviations : CFS, NUHS
Plan
| Supported by the National Institutes of Health (AI 105781 [to B.K. and L.J.]). The study sponsor played no role in the study design, the collection, analysis or interpretation of the data, the writing of the report or the decision to submit the manuscript for publication. The authors declare no conflicts of interest. |
Vol 209
P. 130-133 - juin 2019 Retour au numéro
Article précédent
- Impact of American Academy of Pediatrics Palivizumab Guidance for Children ?29 and <35 Weeks of Gestational Age
- Tracy N. Zembles, Glenn M. Bushee, Rodney E. Willoughby
- Evaluation of a Temporal Association between Vaccination and Subdural Hematoma in Infants
- Juliette Fleury, Pauline Scherdel, Eric Frampas, Nathalie Vabres, Caroline Rey-Salmon, Marie Blot, Elise Launay, Martin Chalumeau, Christèle Gras-Le Guen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?